We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand
Read MoreHide Full Article
Key Takeaways
HIMS deepens AI investment to enhance clinical decisions and personalize treatment at scale.
New tools like Labs integrate biomarker diagnostics directly into Hims & Hers' care experience.
Platform expansions in hormone health and weight management build on HIMS' tech-driven model.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , has consistently positioned technology and clinical infrastructure at the core of its operating model. The platform integrates digital intake, electronic medical records (EMR), prescription workflows and fulfillment into a single end-to-end system, allowing licensed providers to deliver personalized care at scale. This infrastructure supports asynchronous consultations, ongoing provider follow-ups and continuous data capture, enabling treatment plans to be adjusted over time based on patient needs rather than one-time encounters.
During 2025, Hims & Hers further deepened this foundation through targeted investments in data and AI. Leadership additions in technology were paired with expanded efforts to build AI-enabled tools that enhance clinical decision-making, improve routing of patients to appropriate providers, and support more personalized treatment pathways. The platform increasingly uses accumulated clinical and behavioral data to connect diagnostics, prescriptions and care delivery more seamlessly.
Recent product launches reinforce this strategy. The introduction of Labs adds longitudinal diagnostic data — such as biomarker testing — directly into the care experience, strengthening the feedback loop between data, providers and treatment decisions. Similarly, expansions into hormone health, weight management and international markets rely on the same core infrastructure, demonstrating how Hims & Hers is leveraging its integrated technology and clinical systems to scale new specialties while maintaining a consistent, data-driven care model.
Teladoc Health, Inc. (TDOC - Free Report) positions technology and data-driven clinical infrastructure as central to its virtual-care ecosystem. TDOC integrates EMRs, clinician workflows and remote monitoring across its Integrated Care and BetterHelp offerings. Teladoc Health continues to advance AI-enabled capabilities, most recently expanding its Clarity platform to include workplace safety monitoring using real-time video and audio analytics. This expansion reflects how Teladoc Health continues to embed AI-driven monitoring and analytics into hospital and health system workflows to support clinical operations beyond traditional virtual visits.
LifeMD, Inc. (LFMD - Free Report) emphasizes deep technology integration as the backbone of its virtual-care model. LFMD operates a proprietary platform that tightly connects EMR, nationwide provider access, diagnostics and pharmacy fulfillment into a single workflow. LifeMD strengthened this infrastructure by launching a state-of-the-art affiliated pharmacy and expanding compounding capabilities. LifeMD also integrated manufacturer partnerships to streamline access to branded GLP-1 therapies. LFMD further reinforced this platform by fully divesting WorkSimpli, positioning LifeMD as a pure-play virtual care and pharmacy company focused on scaling its integrated clinical and technology infrastructure.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 41.1% over the past year, outperforming the industry’s rise of 2.7%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 2.8X is lower than the industry’s average of 4.6X, but is higher than its three-year median of 2.6X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
Image: Bigstock
HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , has consistently positioned technology and clinical infrastructure at the core of its operating model. The platform integrates digital intake, electronic medical records (EMR), prescription workflows and fulfillment into a single end-to-end system, allowing licensed providers to deliver personalized care at scale. This infrastructure supports asynchronous consultations, ongoing provider follow-ups and continuous data capture, enabling treatment plans to be adjusted over time based on patient needs rather than one-time encounters.
During 2025, Hims & Hers further deepened this foundation through targeted investments in data and AI. Leadership additions in technology were paired with expanded efforts to build AI-enabled tools that enhance clinical decision-making, improve routing of patients to appropriate providers, and support more personalized treatment pathways. The platform increasingly uses accumulated clinical and behavioral data to connect diagnostics, prescriptions and care delivery more seamlessly.
Recent product launches reinforce this strategy. The introduction of Labs adds longitudinal diagnostic data — such as biomarker testing — directly into the care experience, strengthening the feedback loop between data, providers and treatment decisions. Similarly, expansions into hormone health, weight management and international markets rely on the same core infrastructure, demonstrating how Hims & Hers is leveraging its integrated technology and clinical systems to scale new specialties while maintaining a consistent, data-driven care model.
TDOC & LFMD’s Integrated Platforms Scaling Clinical Reach
Teladoc Health, Inc. (TDOC - Free Report) positions technology and data-driven clinical infrastructure as central to its virtual-care ecosystem. TDOC integrates EMRs, clinician workflows and remote monitoring across its Integrated Care and BetterHelp offerings. Teladoc Health continues to advance AI-enabled capabilities, most recently expanding its Clarity platform to include workplace safety monitoring using real-time video and audio analytics. This expansion reflects how Teladoc Health continues to embed AI-driven monitoring and analytics into hospital and health system workflows to support clinical operations beyond traditional virtual visits.
LifeMD, Inc. (LFMD - Free Report) emphasizes deep technology integration as the backbone of its virtual-care model. LFMD operates a proprietary platform that tightly connects EMR, nationwide provider access, diagnostics and pharmacy fulfillment into a single workflow. LifeMD strengthened this infrastructure by launching a state-of-the-art affiliated pharmacy and expanding compounding capabilities. LifeMD also integrated manufacturer partnerships to streamline access to branded GLP-1 therapies. LFMD further reinforced this platform by fully divesting WorkSimpli, positioning LifeMD as a pure-play virtual care and pharmacy company focused on scaling its integrated clinical and technology infrastructure.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 41.1% over the past year, outperforming the industry’s rise of 2.7%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 2.8X is lower than the industry’s average of 4.6X, but is higher than its three-year median of 2.6X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.